Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer

John B Sunwoo; Laurie L Herscher; Glenn S Kroog; Giovana R Thomas; Frank G Ondrey; Dianne C Duffey; Beth I Solomon; Carol Boss; Paul S Albert; Linda McCullugh; Susan Rudy; Chris Muir; Suoping Zhai; William D Figg; John A Cook; James B Mitchell; Carter Van Waes

doi:10.1200/JCO.2001.19.3.800

Back

Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer

Journal article

Peer reviewed

Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer

John B Sunwoo, Laurie L Herscher, Glenn S Kroog, Giovana R Thomas, Frank G Ondrey, Dianne C Duffey, Beth I Solomon, Carol Boss, Paul S Albert, Linda McCullugh, …

Journal of clinical oncology, Vol.19(3), pp.800-811

2001-02-01

DOI: https://doi.org/10.1200/JCO.2001.19.3.800

PMID: 11157034

Abstract

PURPOSE: To determine the feasibility of an organ preservation regimen consisting of infusional paclitaxel administered concurrently with radiotherapy to patients with locally advanced head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS: Thirty-three previously untreated patients with stage III or IV tumors were enrolled onto the study. Paclitaxel was administered as a 120-hour continuous infusion every 3 weeks during the course of radiation therapy. Sixteen patients received a paclitaxel dose of 105 mg/m2, and 17 patients received 120 mg/m2. Radiation was delivered in a standard format at 1.8 Gy/d to a total dose of 70.2 to 72 Gy. RESULTS: Three months after therapy, a 76% complete response (CR) at the primary site and a 70% overall CR was achieved. At 36 months, locoregional control was 55.7%, overall survival was 57.8%, and disease-free survival was 51.1%. The median survival duration for all 33 patients was greater than 50 months at the time of this report. Local toxicities including mucositis, dysphagia, and skin reactions were severe but tolerable. All patients retained functional speech, and all but four patients were swallowing food 3 months after treatment. Steady-state plasma concentrations for paclitaxel were not achieved during a 120-hour infusion, suggesting a nonlinear process. Tumor volume quantified by pretreatment computerized tomography imaging was associated with likelihood of response and survival. CONCLUSION: Paclitaxel administered as a 120-hour continuous infusion in combination with radiotherapy is a feasible and promising treatment for patients with advanced HNSCC.

Metrics

14 Record Views

52 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.179 Oncology; 1.179.377 Head And Neck Cancer
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer
Creators: John B Sunwoo - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Laurie L Herscher - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Glenn S Kroog - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Giovana R Thomas - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Frank G Ondrey - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Dianne C Duffey - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Beth I Solomon - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Carol Boss - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Paul S Albert - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Linda McCullugh - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Susan Rudy - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Chris Muir - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Suoping Zhai - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
William D Figg - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
John A Cook - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
James B Mitchell - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Carter Van Waes - From the Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders; Speech and Language Pathology Section, Rehabilitation Medicine Department, Clinical Center; and Branches of Radiation Oncology, Radiation Biology, Biometric Research, and Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD
Publication Details: Journal of clinical oncology, Vol.19(3), pp.800-811
Academic Unit: Miller School of Medicine; UMMG Department of Otolaryngology
Language: English
Resource Type: Journal article
PMID: 11157034
Record Identifier: 991031562252802976